Live Breaking News & Updates on Professor Paul De Souza
Stay updated with breaking news from Professor paul de souza. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Noxopharm Ltd (ASX:NOX, OTC:NOXOF) has welcomed preliminary data of its oncology drug candidate Veyonda®, currently in trial in combination with Bristol. ....
Noxopharm Ltd's IONIC trial advances; Veyonda oncolytic drug passes safety milestone proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of. ....
Share this article Share this article CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ Harbour BioMed ( HBM , HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) and other type of tumors will be enrolled (study no. 4003.1). The objective of this study is to evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 as a single agent in multiple solid tumor types. The part 1 of phase I trial study results have been submitted to European Society of Medical Oncology (ESMO). ....